Biomaterial Database

Prevention of suxamethonium-induced changes in serum potassium concentration by hexafluorenium. Is their combined use justified? 1979

P A Radnay, and R P Badola, and A Dalsania, and E I El-Gaweet, and D Duncalf

Sixty patients, none of whom was suffering from renal failure, received neurolept anaesthesia. They were divided into six groups of 10 patients each. Groups I and IV, II and V, and III and VI were given suxamethonium 0.2, 0.6 and 1.0 mg kg-1 respectively. Groups IV-VI were pretreated with hexafluorenium 0.3 mg kg-1. The serum potassium concentration decreased significantly after the induction of anaesthesia and also following the administration of hexafluorenium. Neither suxamethonium 0.2 mg nor 0.6 mg kg-1 with or without hexafluorenium restored the potassium concentration to the control value. Suxamethonium 1.0 mg kg-1 alone caused the serum potassium to increase to values greater than control; hexafluorenium attenuated this effect. The combination of hexafluorenium and suxamethonium may be of benefit in patients who are anephric or are in chronic renal failure.

UI	MeSH Term	Description	Entries
D008297	Male		Males
D008875	Middle Aged	An adult aged 45 - 64 years.	Middle Age
D009458	Neuroleptanalgesia	A form of analgesia accompanied by general quiescence and psychic indifference to environmental stimuli, without loss of consciousness, and produced by the combined administration of a major tranquilizer (neuroleptic) and a narcotic.	Neuroleptoanalgesia
D011188	Potassium	An element in the alkali group of metals with an atomic symbol K, atomic number 19, and atomic weight 39.10. It is the chief cation in the intracellular fluid of muscle and other cells. Potassium ion is a strong electrolyte that plays a significant role in the regulation of fluid volume and maintenance of the WATER-ELECTROLYTE BALANCE.
D004357	Drug Synergism	The action of a drug in promoting or enhancing the effectiveness of another drug.	Drug Potentiation,Drug Augmentation,Augmentation, Drug,Augmentations, Drug,Drug Augmentations,Drug Potentiations,Drug Synergisms,Potentiation, Drug,Potentiations, Drug,Synergism, Drug,Synergisms, Drug
D005207	Fasciculation	Involuntary contraction of the muscle fibers innervated by a motor unit. Fasciculations may be visualized as a muscle twitch or dimpling under the skin, but usually do not generate sufficient force to move a limb. They may represent a benign condition or occur as a manifestation of MOTOR NEURON DISEASE or PERIPHERAL NERVOUS SYSTEM DISEASES. (Adams et al., Principles of Neurology, 6th ed, p1294)	Fasciculation, Benign,Fasciculation, Muscular,Fasciculation, Skeletal Muscle,Fasciculation, Tongue,Benign Fasciculation,Benign Fasciculations,Fasciculations,Fasciculations, Benign,Fasciculations, Muscular,Fasciculations, Skeletal Muscle,Fasciculations, Tongue,Muscle Fasciculation, Skeletal,Muscle Fasciculations, Skeletal,Muscular Fasciculation,Muscular Fasciculations,Skeletal Muscle Fasciculation,Skeletal Muscle Fasciculations,Tongue Fasciculation,Tongue Fasciculations
D005260	Female		Females
D005449	Fluorenes	A family of diphenylenemethane derivatives.
D006584	Hexamethonium Compounds	Compounds containing the hexamethylenebis(trimethylammonium) cation. Members of this group frequently act as antihypertensive agents and selective ganglionic blocking agents.	Compounds, Hexamethonium
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man